BRIAN BULL, M.D.
Medical Practice at Anderson St, Loma Linda, CA

2011030, Dec 8, 2011

Apr 25, 2011

13/093825

James P. Collman - Stanford CA, US
Paul Clifford Herrmann - Loma Linda CA, US
David Alvin Tyvoll - La Jolla CA, US
Richard Decreau - Cedex, FR
Brian Stanley Bull - Loma Linda CA, US
Christopher Jeffrey Barile - San Carlos CA, US

Stanford University - Palo Alto CA

A61K 31/4192, C07D 277/02, C07F 9/54, C07D 257/04, C07D 277/40, C07D 277/22, C07D 277/24, C07D 209/12, C07D 233/84, C07D 239/26, C07D 339/04, A61K 31/41, A61K 31/426, A61K 31/4164, A61K 31/404, A61K 31/505, A61K 31/385, A61P 7/02, A61P 9/10, A61P 9/04, A61P 3/00, A61P 9/12, A61P 3/10, A61P 9/00, C07D 249/06

514256, 548255, 548146, 548119, 548253, 548250, 548251, 548254, 548252, 5483241, 548199, 548202, 548203, 548491, 5483251, 544242, 549 39, 514359, 514381, 514370, 514365, 514392, 514415, 514398, 514440

It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

5506145, Apr 9, 1996

Dec 2, 1994

8/348345

Brian S. Bull - Loma Linda CA
Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Old Saybrook CT

G01N 3386, G01N 3372

436 69

Useful information about a subject's level of systemic inflammation is obtained by quantitatively measuring the amount of fibrinogen and the hematocrit and or hemoglobin in the subject's whole blood. The fibrinogen measurement, when combined with an hematocrit or hemoglobin measurement, provides a systemic Inflammation Index value for the donor. The method is not affected by blood variables which are not related to the presence of inflammation, which blood variables are known to invalidate an erythrocyte sedimentation rate, which is the most frequently used blood test for detecting systemic inflammation in humans.

5594164, Jan 14, 1997

Jul 12, 1994

8/270681

Brian S. Bull - Loma Linda CA

G01N 3349

73 6166

An apparatus and method for rapid determination of erythrocyte sedimentation rates for a blood specimen (29) which can be linearly transposed to Westergren sedimentation rates. The method includes the steps of inducing accelerated rouleaux formation in the specimen (29) in an amount sufficient to begin settling at substantially the decantation rate for the specimen. In one embodiment a structure (27) which produces a very thin cross-sectional region (37) of the specimen (29) inside the lumen (23) of a specimen container (21) is provided to accelerate rouleaux formation. In an alternative embodiment (120), accelerated rouleaux formation is accomplished using a centrifuge (122). A third embodiment employs a movable rod (223) mounted inside the specimen tube (221) to induce accelerated rouleaux formation. All embodiments of the process next employ gravity settling the specimen in a near horizontal oriented container (21, 121, 221). Thereafter, the amount of settling occurring is determined.

6098451, Aug 8, 2000

Nov 30, 1998

9/201321

Brian S. Bull - Loma Linda CA

G01N 3349

73 6166

An apparatus and method for rapid determination of erythrocyte sedimentation rates for a blood specimen (29) which can be linearly transposed to Westergren sedimentation rates. The method includes the steps of inducing accelerated rouleaux formation in the specimen (29) in an amount sufficient to begin settling at substantially the decantation rate for the specimen. In one embodiment a structure (27) which produces a very thin cross-sectional region (37) of the specimen (29) inside the lumen (23) of a specimen container (21) is provided to accelerate rouleaux formation. In an alternative embodiment (120), accelerated rouleaux formation is accomplished using a centrifuge (122). A third embodiment employs a movable rod (223) mounted inside the specimen tube (221) to induce accelerated rouleaux formation. All embodiments of the process next employ gravity settling the specimen in a near horizontal oriented container (21, 121, 221). Thereafter, the amount of settling occurring is determined.

5716796, Feb 10, 1998

Jan 29, 1996

8/593483

Brian S. Bull - Loma Linda CA
Ralph A. Korpman - Redlands CA

Medical Devices Corporation - San Bernardino CA

C12Q 156, B05D 700

435 13

A method for optically measuring the functional capacity of blood platelets and the blood clotting system. The method consists of detection of platelet aggregation in a platelet-containing specimen fluid, whereby the specimen fluid is contacted with a platelet agonist and disclosure reagent. A mechanical specimen-handling apparatus with one or more optical end-point detectors which is preferred for use with the method of the invention is also described. The apparatus incubates a small quantity of diluted whole blood with added solid or liquid reagents at body temperature, and mixes the blood via rocking and rotational motions so as to expose the blood uniformly to the reagents. The optical end-point detectors then measure the activity of platelets within the blood specimen, clotting time, and the clotting cascade. Several intermediate measurements are also available.

5275953, Jan 4, 1994

Apr 22, 1991

7/688892

Brian S. Bull - Loma Linda CA

C12Q 156, G01N 3348

436 69

A blood extracting and receiving container assembly (10) having a coating agent (22) disposed on an interior surface of a blood receiving chamber (12) and an extracting apparatus (14) to effectively isolate a blood specimen from contacting surfaces which would initiate clotting. The coating agent contains molecules which inhibit the activation of blood elements responsible for initiating blood clotting processes. A method for manipulating a blood specimen in vitro in association with the subject blood extracting and receiving assembly (10) includes the steps of coating an interior surface of the extracting and receiving container assembly (10) with nonthrombogenic coating agent (22), and, while coating agent (22) adheres to the interior surface of assembly (10), withdrawing a blood specimen (24) into the assembly. Additionally, the method includes the steps of exposing the specimen to an activating surface in a controlled manner to initiate blood clotting processes, preferably while a portion of the specimen is admixed with the nonthrombogenic agent. A clotting parameter, such as weight or clotting rate, may be correlated with a disease condition.

5731513, Mar 24, 1998

Sep 17, 1996

8/718637

Brian S. Bull - Loma Linda CA

G01N 3349, G01N 1504, B01D 2126

73 6166

An apparatus and method for rapid determination of erythrocyte sedimentation rates for a bloodspecimen (29) which can be linearly transposed to Westergren sedimentation rates. The method includes the steps of inducing accelerated rouleaux formation in the specimen (29) in an amount sufficient to begin settling at substantially the decantation rate for the specimen. In one embodiment a structure (27) which produces a very thin cross-sectional region (37) of the specimen (29) inside the lumen (23) of a specimen container (21) is provided to accelerate rouleaux formation. In an alternative embodiment (120), accelerated rouleaux formation is accomplished using a centrifuge (122). A third embodiment employs a movable rod (223) mounted inside the specimen tube (221) to induce accelerated rouleaux formation. All embodiments of the process next employ gravity settling the specimen in a near horizontal oriented container (21, 121, 221). Thereafter, the amount of settling occurring is determined.

2011023, Sep 29, 2011

Mar 11, 2011

13/045978

Brian Stanley Bull - Loma Linda CA, US

A63B 21/02

482126

An exercise device for strengthening the small muscles and tendons that stabilize the inner and outer parts of the elbow includes a hollow outer housing, an inner housing adapted to slide into and out of the hollow outer housing, a plurality of elastic bands placed inside the interior of the inner housing, a slot located along the sidewalls of the hollow outer housing, a connector secured to the inner housing and passing through the slot of the hollow outer housing, and the inner housing is adapted to slide from a retracted position to an extended position against the resistance provided by one or more elastic bands.

7264579, Sep 4, 2007

May 27, 2004

10/856636

Brian S. Bull - Loma Linda CA, US

A63B 21/02

482121, 482126

A device and method for preventing the damage underlying lateral epicondylitis (tennis elbow) or medial epicondylitis (golfer's elbow), or both lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer's elbow), or for treating the damage underlying lateral epicondylitis (tennis elbow) or medial epicondylitis (golfer's elbow), or both lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer's elbow). The device comprises a central support (), and one or more than one extension-adduction apparatus () or one or more than one flexion-abduction apparatus (), or both one or more than one extension-adduction apparatus () and one or more than one flexion-abduction apparatus ().